Current ulcerative colitis (UC) treatments have variable efficacy and may take several weeks to assess improvement. Emerging data suggest the intestinal microbiota may serve as a biomarker and mechanistically may influence immune system activity through epigenetic regulation of host gene expression. The aim of this pilot project was to examine whether the colonic mucosal microbiota and mucosal DNA methylation patterns are associated with a response to treatment in UC.